BNGO vs SINT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BNGO exhibits severe financial distress despite modest revenue growth, as reflected in its Piotroski F-Score of 1/9—indicating weak operational and financial health. The absence of an Altman Z-Score and the company's negative profitability metrics (e.g., -134.36% profit margin, -78.22% ROE) signal deep operational inefficiencies and high risk of insolvency. Although the stock shows a recent technical uptick and strong earnings surprise history, these are overshadowed by deteriorating fundamentals, massive losses, and a 5-year price decline of 100%. The lack of a Graham Number and intrinsic value estimate further underscores the absence of a reliable valuation anchor. Analysts have a target price of $5.50, but this is not supported by current fundamentals and appears speculative.
SINT exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -787.59%. The company is experiencing a collapse in its top line with YoY revenue growth at -46.50% and a consistent track record of missing earnings estimates (0/4 beats in the last year). Despite a 'Strong Buy' analyst consensus and a target price of $10.17, the fundamental data suggests a company in a death spiral with a 5-year price change of -100%. The disconnect between analyst optimism and the deterministic health scores indicates extreme speculative risk.
Compare Another Pair
Related Comparisons
BNGO vs SINT: Head-to-Head Comparison
This page compares Bionano Genomics, Inc. (BNGO) and Sintx Technologies, Inc. (SINT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.